Non-Invasive Blood and Stool CRC Screening Tests: Available Modalities and Their Clinical Application (GI & Hepatology News)

Noninvasive CRC screening is getting crowded — but not all “easy” tests are created equal.
This new review compares FIT, multitarget stool DNA (Cologuard / Cologuard Plus), the next-gen stool RNA test (ColoSense), and emerging blood-based tests like Shield. The takeaway is blunt: stool-based tests still outperform today’s blood tests on effectiveness and cost, especially for advanced precancerous lesions. Blood-based tests should be reserved for patients who refuse colonoscopy and stool options — at least until sensitivity, adenoma detection, and pricing improve.